Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors

Bioorg Chem. 2020 Jan:94:103356. doi: 10.1016/j.bioorg.2019.103356. Epub 2019 Nov 21.

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in tumor immune escape and has emerged as a promising target for cancer immunotherapy. In this study, a novel series of bicyclic carboxylic acid derivatives were designed, synthesized and evaluated for inhibitory activities against IDO1. Among these, compound 9c exhibited strong IDO1 inhibitory activity (HeLa cellular IC50 = 2.6 nM, THP-1 cellular IC50 = 11.2 nM). Further anti-tumor studies in vivo have shown that compound 9c has a great inhibitory effect on tumor growth in mice CT26 model as a single agent or in combination with 5-fluorouracil (inhibition rate was 53.9% and 92.7%, respectively). These results indicate that compound 9c is a effective IDO1 inhibitor for further investigation.

Keywords: Hela cell assay; IDO1 inhibitors; Immunotheraphy; l-tryptophan.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carboxylic Acids / chemical synthesis
  • Carboxylic Acids / chemistry*
  • Carboxylic Acids / pharmacology*
  • Drug Design*
  • HeLa Cells
  • Humans
  • Indoleamine-Pyrrole 2,3,-Dioxygenase / antagonists & inhibitors*
  • Molecular Docking Simulation
  • THP-1 Cells

Substances

  • Carboxylic Acids
  • IDO1 protein, human
  • Indoleamine-Pyrrole 2,3,-Dioxygenase